Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study

Jorge J. Castillo, Mark Bower, Jérémy Brühlmann, Urban Novak, Hansjakob Furrer, Paula Y. Tanaka, Caroline Besson, Silvia Montoto, Kate Cwynarski, Jeremy S. Abramson, Samir Dalia, Michele Bibas, Joseph M. Connors, Michael Furman, Minh Ly Nguyen, Timothy P. Cooley, Brady E. Beltran, Jaime A. Collins, Julie M. Vose, Blanca XicoyJosep Maria Ribera

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The treatment and outcomes of patients with human immunodeficiency virus (HIV)-associated Hodgkin lymphoma (HL) continue to evolve. The International Prognostic Score (IPS) is used to predict the survival of patients with advanced-stage HL, but it has not been validated in patients with HIV infection. METHODS: This was a multi-institutional, retrospective study of 229 patients with HIV-associated, advanced-stage, classical HL who received doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) plus combination antiretroviral therapy. Their clinical characteristics were presented descriptively, and multivariate analyses were performed to identify the factors that were predictive of response and prognostic of progression-free survival (PFS) and overall survival (OS). RESULTS: The overall and complete response rates to ABVD in patients with HIV-associated HL were 91% and 83%, respectively. After a median follow-up of 5 years, the 5-year PFS and OS rates were 69% and 78%, respectively. In multivariate analyses, there was a trend toward an IPS score >3 as an adverse factor for PFS (hazard ratio [HR], 1.49; P=.15) and OS (HR, 1.84; P=.06). A cluster of differentiation 4 (CD4)-positive (T-helper) cell count

Original languageEnglish
Pages (from-to)423-431
Number of pages9
JournalCancer
Volume121
Issue number3
DOIs
Publication statusPublished - Feb 1 2015

Keywords

  • And dacarbazine
  • Antiretroviral therapy
  • Bleomycin
  • CD4 count
  • Doxorubicin
  • Hodgkin lymphoma
  • Human immunodeficiency virus
  • Vinblastine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study'. Together they form a unique fingerprint.

  • Cite this

    Castillo, J. J., Bower, M., Brühlmann, J., Novak, U., Furrer, H., Tanaka, P. Y., Besson, C., Montoto, S., Cwynarski, K., Abramson, J. S., Dalia, S., Bibas, M., Connors, J. M., Furman, M., Nguyen, M. L., Cooley, T. P., Beltran, B. E., Collins, J. A., Vose, J. M., ... Ribera, J. M. (2015). Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study. Cancer, 121(3), 423-431. https://doi.org/10.1002/cncr.29066